
Keywords: ER-positive breast cancer; Metabolic pathway; Neoadjuvant chemotherapy; Chemo-sensitivity; Prognosis predictionER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; DMFS, distant metastasis-free survival; pCR, p